Aquestive Therapeutics Secures $75 Million to Propel Next-Generation Oral Therapies in CNS and Allergy Care

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is delighted to announce that it has successfully raised $75,000,000 in its latest funding round. This strategic investment empowers the pharmaceutical company to accelerate its mission of transforming patient care by advancing orally administered medicines that offer viable alternatives to traditional, invasive therapies. With a robust track record that includes five U.S.-commercialized products—complemented by four licensed products and one groundbreaking proprietary product, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut Syndrome—Aquestive is uniquely positioned at the intersection of innovation and patient need. The infusion of capital will be fundamentally directed towards expanding the company’s late-stage product pipeline focused on disorders of the central nervous system (CNS), while also bolstering earlier stage research efforts aimed at combating severe allergic reactions, including anaphylaxis. By leveraging proprietary technologies such as PharmFilm® and its proven drug development and commercialization capabilities, Aquestive plans to not only enhance its existing portfolio but also catalyze the introduction of new, transformative therapies that simplify and improve patient quality of life. Investors in this round share the vision of a company poised to redefine standards of care with novel, orally administered products, proving that innovative pharmaceutical strategies can lead to more accessible and convenient treatment options worldwide. This robust funding achievement is a testament to market confidence in Aquestive’s innovative approach and its long-term potential to positively impact health outcomes for patients around the globe.